JCAR-023

N/A

Report date: 2022/09/05 20:00:48

Base Information

Drug NameJCAR-023
Drug Alias NameJCAR-023
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsNeural cell adhesion molecule L1 modulators
TargetsNeural cell adhesion molecule L1
Therapy Area/IndicationsGanglioneuroblastomaNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Research InstituteSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S HospitalJuno Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGanglioneuroblastomaNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A